{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-027540","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.329471+00:00","generated_at":"2026-06-17T06:09:46.087230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmuCell Q1 2023 sales $3.45M, down 43% YoY; backlog rises to $7.5M","bullets":["Q1 2023 sales $3.45M vs $6.00M in Q1 2022, a 43% decrease due to production slowdown from contamination events.","Trailing twelve months sales $16.01M vs $21.14M, down 24%.","Backlog of orders increased to $7.5M as of March 31, 2023, from $2.5M at Dec 31, 2022.","Quality control improvements: first test pass rate 82%, subsequent tests 100% success; production ramping up in Q2.","Expects third submission of CMC Technical Section for Re-Tain FDA approval around end of April 2023, subject to six-month review."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-027540","json":"https://secwatch.observer/filing/0001213900-23-027540.json","markdown":"https://secwatch.observer/filing/0001213900-23-027540.md","text":"https://secwatch.observer/filing/0001213900-23-027540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/0001213900-23-027540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/ea176604-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:09:46.087230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b009b9b22f70caa7e70fa7d4541d85487204b01","claim":"IMMUCELL CORP /DE/ reported the first quarter of 2023, which ended March 31, 2023 results: revenue $3.45 million.","evidence_excerpt":"unaudited sales results for the first quarter of 2023, which ended March 31, 2023. 2023 2022 ($ Decrease) (% Decrease) During the Three-Month Periods Ended March 31, $3.45 million $6.00 million ($2.55 million) (43 )% During the Twelve-Month Periods Ended March 31, $16.01 million $21.14 million ($5.12 million) (24 )% Actual sales during the first quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/0001213900-23-027540-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023, which ended March 31, 2023"},{"label":"Revenue","value":"$3.45 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}